| Total, n
|
|
67 |
| Median age at PT biopsy, years |
|
51,9 |
| Median age at MT biopsy, years |
|
56,9 |
| Phenotype of primary tumor by IHC, n (%) |
|
|
| Luminal A |
|
25 (37%) |
| Luminal B (HER2-negative) |
|
15 (22%) |
| Luminal B (HER2-positive) |
|
2 (3%) |
| HER2 positive (non-luminal) |
|
6 (9%) |
| Triple-negative |
|
17 (25%) |
| NA |
|
2 (3%) |
| Grading of primary tumor, n (%) |
| G1 |
|
|
| G1 |
|
0 (0%) |
| G2 |
|
40 (60%) |
| G3 |
|
20 (30%) |
| GX |
|
7 (10%) |
| ER/ESR1 status of primary tumor, n (%) |
IHC |
RTqPCR |
| Positive |
44 (66%) |
42 (63%) |
| Negative |
23 (34%) |
24 (36%) |
| Unknown |
0 (0%) |
1 (2%) |
| PR/PGR status of primary tumor, n (%) |
|
|
| Positive |
42 (63%) |
29 (43%) |
| Negative |
25 (37%) |
37 (55%) |
| Unknown |
0 (0%) |
1 (2%) |
| HER2/ERBB2 status of primary tumor, n (%) |
|
|
| Positive |
14 (21%) |
8 (12%) |
| Negative |
39 (58%) |
58 (87%) |
| Unknown |
14 (21%) |
1 (2%) |
| Site of metastatic biopsy, n (%) |
|
|
| Bone |
|
24 (36%) |
| Brain |
|
19 (28% |
| Liver |
|
8 (12%) |
| Lung |
|
2 (3%) |
| Pleura |
|
3 (5%) |
| Soft tissue |
|
11 (16%) |
